doi: 10.1519/00124278-200702000-00046
Dehydration is a more serious concern for patients on semaglutide, especially those with fibromyalgia who may already struggle with fatigue and irregular fluid intake
[1] Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations
Factors that influence dosing include: Overall health and cardiovascular status Use of androgen deprivation therapy or hormone suppression Sensitivity to peptide therapies Concurrent use of other erectile dysfunction treatments Because PT-141 acts on the melanocortin system, higher doses do not necessarily produce better results and may increase the likelihood of side effects
Often skin imperfections and uneven pigmentation can cause social anxiety and self-consciousness
Older oral options produce more modest results (511%) but offer advantages in cost, convenience, or tolerability for certain patients